Pre-made Omburtamab benchmark antibody ( Whole mAb Radiolabelled, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Omburtamab biosimilar, Whole mAb Radiolabelled, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Omburtamab (formerly burtomab) is a theranostic monoclonal antibody 8H9, conjugated to to 131 iodine, being developed by Y-mAbs Therapeutics, under a license from Memorial Sloan-Kettering Cancer Center, for the diagnosis and treatment of cancer.
| Products Name (INN Index) | Pre-Made Omburtamab biosimilar, Whole mAb Radiolabelled, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody |
|---|---|
| INN Name | Omburtamab |
| Target | CD276 |
| Format | Whole mAb Radiolabelled |
| Derivation | Mouse |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | 5cma:BA |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Memorial Sloan-Kettering Cancer Center,Y-mAbs Therapeutics |
| Conditions Approved | NA |
| Conditions Active | Neuroblastoma,Meningeal carcinomatosis,Soft tissue sarcoma,Peritoneal cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD276 |
| Package |
